Navigation Links
New robotic head and neck cancer surgery preserves speech, without scarring
Date:9/7/2010

DETROIT An incisionless robotic surgical procedure is offering patients a new option to remove certain head and neck cancer tumors without visible scarring, while preserving speech and the ability to eat.

Henry Ford Hospital in Detroit is among the first in the country to perform TransOral Robotic Surgery (TORS) using the da Vinci Surgical System. Unlike traditional surgical approaches to head and neck cancer, TORS patients are able to return to their normal lives only a few days after surgery without significant pain and disfigurement.

"TORS offers shorter post-operative recovery than standard open surgical approaches, giving patients the opportunity to quickly and successfully return to their normal lives," says Tamer A. Ghanem, M.D., Ph.D., director of Head and Neck Oncology and Reconstructive Surgery Division in the Department of OtolaryngologyHead & Neck Surgery at Henry Ford Hospital.

"TORS allows surgeons to completely remove tumors of the head and neck while preserving speech, swallowing, and other key quality of life issues such as eating. There also is no visible scaring or disfigurement."

Led by Dr. Ghanem, Henry Ford Hospital has performed more than a dozen TORS procedures since it was approved in January by the U.S. Food and Drug Administration to remove malignant and benign tumors of the mouth, tongue, tonsils, and parts of the throat.

Prior to TORS, patients would traditionally begin treatment with radiation therapy, or a combination of chemotherapy and radiation therapy, depending on the stage of their cancer. Side effects of radiation dry mouth, loss of taste and difficulty swallowing can potentially be avoided with TORS

Traditional surgery has side effects as well. It requires a long incision be made across the lip and jaw to access the tumor. This approach can results in significant swelling, longer post-operative recovery, damage to surrounding structures, and speech and swallowing problems.

With TORS, surgeons can access tumors through the mouth using the slender operating arms of the da Vinci, thus not requiring an open skin incision.

"Surgeons operate with greater precision and control using the TORS approach," says Dr. Ghanem, "minimizing the pain, and reducing the risk of possible nerve and tissue damage associated with large incisions."

Some of TORS's other benefits include:

  • Significantly less blood loss
  • No visible scarring
  • Possibility of avoiding a tracheotomy
  • Minimization or elimination of need for chemoradiation therapy
  • Fewer complications and shorter hospital stay
  • Faster recovery, return to normal speech and swallowing
  • Equivalent cancer control to radiation therapy

Patients with early stage tonsil and base of tongue cancers may not need to receive radiation therapy following TORS, depending on the final tumor margins and pathological characteristics of the tumor.

In addition to TORS, Dr. Ghanem specializes in complex head and neck oncology cases, offering both cancer resection as well as reconstructive surgery using microvascular techniques (taking tissue from one part of the body and transplanting it to the head and neck areas to improve function and esthetics). In addition, he performs thyroid, parathyroid, and salivary gland surgery, reconstruction after Mohs procedures and robotic-assisted thyroidectomy, in which the incision is made in the arm pit instead of the neck to conceal it.


'/>"/>

Contact: Krista Hopson
khopson1@hfhs.org
313-874-7207
Henry Ford Health System
Source:Eurekalert  

Related medicine news :

1. Pre-emptive pain regimen decreased opioid usage in patients undergoing robotic prostatectomy
2. Robotic-assisted vasectomy reversal offers greater chance of fatherhood
3. Introducing RoSS, a flight simulator for robotic surgery
4. LA BioMed research finds hallucinogen can safely ease anxiety in advanced-stage cancer patients
5. Hallucinogen appears safe, may improve mood among patients with advanced-stage cancer and anxiety
6. Long-Term Use of Bone Drugs May Be Linked to Esophageal Cancer
7. Basal-like breast cancer does not originate from basal stem cells
8. Study finds that cancer-causing gene crucial in stem cell development
9. Microsoft Excel-based algorithm predicts cancer prognosis
10. Diabetes Drug Metformin Linked to Lower Lung Cancer Rate in Mice
11. Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New robotic head and neck cancer surgery preserves speech, without scarring
(Date:10/13/2017)... ... 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board of ... Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve ... Puffer’s retirement at the end of 2018. Upon assuming the role of President and ...
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of ... ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership in ... It also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Many families have ... many long-term care insurance companies have a waiver for care if the client has ... period, when the family pays for care, is often waived, so the benefits from ...
(Date:10/13/2017)... ... 2017 , ... Ellevate Network, the leading network for professional women, brought together ... equality at their inaugural Summit in New York City in June. The event was ... of over 3 million. To watch the Mobilize Women video, click here . ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
Breaking Medicine Technology: